BiotechTube

Pembrolizumab + Lenvatinib

Phase 2Completed
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer

Trial Timeline

Dec 15, 2017 → May 13, 2024

NCT ID
NCT03290079

About Pembrolizumab + Lenvatinib

Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03290079. Target conditions include Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumors were approved

Approved (6) Terminated (2) Active (9)
✅Everolimus (RAD001)NovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved
✅sunitinibPfizerApproved
✅lanreotide acetateIpsenApproved
✅lanreotide (Autogel formulation)IpsenApproved
🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (13)

NCT IDPhaseStatus
NCT07011849Phase 2Withdrawn
NCT06266338Phase 2Recruiting
NCT05545969Phase 2Withdrawn
NCT04865887Phase 2Recruiting
NCT05273554Phase 1Active
NCT04955743Phase 2Terminated
NCT05147558Phase 2Active
NCT05078931Phase 2Active
NCT04848337Phase 2Active
NCT04729348Phase 2Terminated
NCT04287829Phase 2Active
NCT04207086Phase 2Active
NCT03290079Phase 2Completed

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
LenvatinibEisaiPhase 2
35
AbemaciclibEli LillyPhase 2
39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
47
FamitinibJiangsu Hengrui MedicinePhase 2
27
68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3
47
OlaparibAstraZenecaPhase 2
27
AvelumabMerckPhase 1/2
32
PembrolizumabMerckPhase 2
27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-PyruvateMerckPhase 2
42
PembrolizumabMerckPhase 2
35
Pembrolizumab InjectionMerckPhase 2
27
Carboplatin + Cisplatin + Docetaxel + Etoposide + PembrolizumabMerckPhase 1
33
AvelumabMerckPhase 2
35
AvelumabMerckPhase 2
35
Pembrolizumab + Irinotecan + PaclitaxelMerckPhase 2
35
MK-0646MerckPhase 2
35
Lanreotide + PembrolizumabMerckPhase 1/2
32